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Abstract
The results of cytotoxicity trials against a panel of seven human cell lines for a series of
triorganophosphinegold(I) 3- and 4-mercaptobenzoates are reported. While the new compounds show
moderate to high toxicity, their potencies are inferior to those reported previously for their isomeric 2-
mercaptobenzoate derivatives. The results therefore suggest a structure-activity relationship in that the 2-
isomeric species are more active, particularly against the non-small cell lung cancer and renal cancer cell
lines, results that may indicate some selectivity in their cytotoxic profile.
Introduction
Gold complexes are well known to possess significant anti-arthritic activity and several gold thiolates are
currently used clinically in the treatment of that disease [1-3]. In addition to this biological profile, several
gold(I), as well as gold(Ill) species, have proven to display cytotoxicity and anti-tumour activity as
summarised in a recent survey [4]. In this context, one of the active classes of compounds features a linear
P-Au-S entity as found in the anti-arthritic drug, auranofin (triethylphosphinegold(I)
tetraacetatothioglucose). Our work in this area has focussed on making derivatives of auranofin, some of
which display significant cytotoxicity and anti-tumour activity [5-8]. A difficulty encountered with these
compounds has been their limited aqueous solubility. In order to overcome this limitation, thiols containing
water-solubilising groups have been coordinated to the phosphinegold(I) entity. Amongst the thiols chosen
for investigation was 2-mercaptobenzoic acid. These derivatives displayed moderate to high cytotoxicity
profiles compared to standards such as cisplatin, doxorubicin, methotrexate, etc. [9]. In particular,
significant cytotoxicity was found against the non-small cell lung cancer and renal cancer cell lines. As a
continuation of work in this area, some 3- and 4-mercaptobenzoates have been prepared and subjected to
screening for their cytotoxicity profiles. The results ofthis study are reported herein.
Results and Discussion
The triorganophosphinegold(I) n-mercaptobenzoates, R3PAu(n-mbaH), have been synthesised using
established procedures involving the metathesis of the triorganophosphinegold(I) chloride precursor with
the appropriate n-mercaptobenzoic acid in the presence of base. Characterisation data are collected in the
Experimental section. A number of the n-mercaptobenzoates compounds have been characterised
crystallographically, by us [9 11] (i.e. n 2 for R Ph and Cy; n 3 for R Cy and Ph) and others [12]
(i.e. n 4 for R Et).
The crystal structure of Cy3PAu(4-mbaH) has been determined in the present study. A
centrosymmetrically related pair of molecules is illustrated in Figure 1; selected geometric parameters are
collected in the Figure caption. The gold atom exists in the expected linear geometry defined by the sulfur
and phosphorus atoms so that the angle subtended at the gold atom is 175.06(4). The 4-mbaH ligand is
essentially planar as seen in the magnitude of the O1/CI’/C1/C2 and O2/C1’/C1/C2 torsion angles of-
174.3(4) and 5.0(7), respectively. Molecules associated via the familiar carboxylic acid dimer motif with
the key parameters defining this association listed in the caption to Figure 1. The structure is in essential
agreement with the Et3PAu(4-mbaH) and o-tol3PAu(4-mbaH) structures reported recently by Schmidbaur et
al. [12].
A previous report [9] summarising the cytotoxicity of a series of triorganophosphine 2-
mercaptobenzoates showed high levels of activity, in particular against the non-small cell lung cancer
(H226) and renal cancer (A498) cell lines. These results are reproduced in Table 1. Subsequently,
biological trials for some 3- and 4-mercaptobenzoate derivatives of R3PAu, for R Et, Cy & Ph, were also
conducted.
As seen from Table 1, a general structure-activity relationship can be established in that the 2-
mercaptobenzoate compounds are generally more active than their 3- and 4- isomeric counterparts. The
most cytotoxic compound in the series investigated was the Et3PAu(2-mbaH) compound which displayed a
IDs0 value of 43 ng/ml against the IGROV cell line but, doxorubicin and methotrexate were more active.
High activity against the H226 and A498 cell lines was only observed for the 2-mbaH series perhaps
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indicating some selectivity in activity. It would be of some interest to ascertain whether this activity is
maintained in vivo leading to anti-tumour activity.
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Figure 1. The centrosymmetric hydrogen-bonded dimer of Cy3PAu(4-mbaH) (50% probability level).
Selected bond distances and angles: Au-S4 2.308(2), Au-P1 2.273(1), $4-C4 1.759(5), CI’-OI 1.280(5),
C1’-O2 1.250(5) A;, S4-Au-P1 175.06(4), Au-S4-C4 105.53(15). Parameters associated with the hydrogen
bonding interaction are O1-H...O2’ 1.81 A, O1...O2’ 2.628(5) A and an angle subtended at H of 166;
symmetry operation-l-x, l-y, 1-z.
Table 1. In vitro IDs0 values (ng/ml) for R3PAu(n-mbaH), n 2, 3 & 4 and R Et, Cy & Ph, using the
microculture sulforhodamine B (SRB) test as cell viability, and for the reference compounds: doxorubicin
(DOX), cisplatin (CPT), 5-fluorouracil (5-FU), methotrexate (MTX) and etoposide (ETO)
R n Cell Line
MCF7 EVSA-T WIDR IGROV M19MEL A498 H226
Et 2 [9] 405 110 984 43 118 65 69
Cy 2 [9] 411 225 772 182 292 95 97
Ph 2 [9] 791 356 982 117 298 151 173
Cy 3 806 1046 949 283 403 697 848
Ph 3 1065 1287 957 280 797 1274 960
Et 4 1145 1197 1238 67 375 484 864
Cy 4 973 1353 976 338 592 743 923
Ph 4 858 940 553 148 322 348 586
standards
DOX 8 11 10 16 60 90 199
CPT 422 967 699 558 169 2253 3269
5-FU 475 225 750 442 297 143 340
MTX 5 <3 18 23 7 37 2287
ETO 317 150 2594 505 580 1314 3934
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Experimental
Preparations
The R3PAu(n-mbaH) compounds were prepared by literature procedures established for the
triorganophosphine 2-mercaptobenzoates [9]. Characterisation details for the n 3, R Cy and Ph
compounds are available in the literature [10]. During the course of the present study, the preparation and
characterisation of the n 4, R Et and Ph derivatives were reported [12]. Full details for the n 4, R
Cy compound are presented below as well as previously unreported spectroscopic details for the n 4, R
Et and Ph compounds.
Cy3PAu(4-mbaH): Yield 71% of colourless crystals that decomposed above 250 C. Crystals for the X-ray
study were grown by the slow evaporation of a CH2CI2/EtOH (1/1) solution of the compound. C, 47.5; H,
6.1.,C2H3sAuO2PS requires C, 47.6; H, 6.1%. IR (KBr disk): v(C=O) 1674(s) and v(O-H) 2500 3200 (br)
cm". "H NMR (d6-DMSO): 6 7.58 (d, 8.4 Hz, H2 of 4-mbaH); 7.42 (d, 8.4 Hz, H3 of 4-mbaH); 12.5 (br,
CO2H). 13C{1H} NMR (d6-DMSO): 124.9, 128.8, 131.0, 151.8, 16732 (4-mbaH: C1, C2, C3, C4, CO2);
32.4 (d, 28.3 Hz, Cot); 26.3 (d, 12.1 Hz, CI); 30.3 (C),), 25.5 ppm (C6). PNMR (d6-DMSO): 15 59.2 ppm.
Et3PAu(4-mbaH): IR (KBr disk): v(C=O) 1688(s) and v(O-H) 2500 3200 (br) cm"1. 13C{H} NMR (d6-
DMSO): t5 124.4, 128.8, 13L1, 151.9, 167.2 (4-mbaH: C1, C2, C3, C4, CO2); 17.0 (d, 33.5 Hz, Ca); 9.0
(CI). 3rpNMR (d6-DMSO): 39.9 ppm.
Ph3PAu(4-mbaH): IR (KBr disk): v(C=O) 1669 (s) and v(O-H) 2500 3200 (br) cml. 13C{1H} NMR (d6-
DMSO): 125.1,129.1, 131.2, 150.8, 167.2 (4-mbaH: C1, C2, C3, C4, CO2); 128.7 (d, 57.0 Hz, Cct); 133.7
(d, 13.7 Hz, CI); 129.6 (d, 11.5 Hz, C,), 132.0 ppm (d, 2.3 Hz, C). alpNMR (d6-DMSO): 38.7 ppm.
Biological screening
The following human tumour cell lines were used: MCF7 (breast cancer), EVSA-T (breast cancer), WIDR
(colon cancer), IGROV (ovarian cancer), M19MEL (melanoma), A498 (renal cancer), and H226 (non-small
cell lung cancer). Cell lines WIDR, M19 MEL, A498, IGROV and H226 belong to the currently used anti-
cancer screening panel of the National Cancer Institute, USA [13]. The MCF7 cell line is estrogen receptor
(ER)+/progesterone receptor (PgR)+ and the cell line EVSA-T is (ER)-/(PgR)-.
Prior to the experiments, a mycoplasma test was carried out on all cell lines and found to be negative. All
cell lines were maintained in a continuous logarithmic culture in RPMI 1640 medium with Hepes and
phenol red. The medium was supplemented with 10% FCS, penicillin 100 IU/ml and streptomycin 100
lag/ml. The cells were mildly trypsinised for passage and for use in the experiments.
Chemicals
RPMI and FCS were obtained from Life Technologies (Paisley, Scotland). SRB, DMSO, penicillin
and streptomycin were obtained from Sigma (St. Louis MO, USA), TCA and acetic acid from Baker BV
(Deventer, NL) and PBS from NPBI BV (Emmer-Compascuum, NL).
Experimental Procedures
The test and reference compounds were dissolved to a concentration of 250000 ng/ml in full medium, by 20
fold dilution of a stock solution which contained mg compound/200lag atter having been dissolved first in
in DMSO solution. Cytotoxicity was estimated by the microculture sulforhodamine B (SRB) test [14].
Table 2. Crystal data for Cy3PAu(4-mbaH)
Empirical formula
Diffractometer
Unit cell dimensions
la (Mo-Kct), cm
"l
0 range,
Reflections collected
No. parameters refined
wR (all data)
C25H38AuO2PS Formula weight 630.57
Rigaku AFC7R Space group monoclinic, P2
a 12.257(6) A Volume, A
3 2532(2)
b 16.559(9)A fl 98.69(3) Z 4
c 12.621(4) A De, g cm
"3 1.654
59.94 F(000) 1256
3.3 27.5 Temperature, K 173
5805 Reflections with 1>2o(/) 4115
272 R [/>20(/)] 0.025
0.060 Goodness-of-fit on F2 1.01
Weighting scheme w [cr2+(0.0287p)2]-1 where P (Fo
2 + 2F2)/3
Diff. hole and peak, eA-3 -0.76 to 1.41 CCDC deposition no.
Programs teXsan 16], DIRDIF 17], SHELXL-97 18], ORTEPII 19]
181875
The experiment was started on day 0. On day 0, 150 lal of trypsinised tumour cells (1500-2000
cells/well) were plated in 96-wells flatbottom microtiter plates (Falcon 3072, BD). The plates were
preincubated for 48 h at 37 C, 8.5% CO2 to allow the cells to adhere. On day 2, a three-fold dilution
sequence of ten steps was made in full medium, starting with the 250000 ng/ml stock solution. Every
dilution was used in quadruplicate by adding 50 lag to a column of four wells. This results in a highest
concentration of 62500 ng/ml present in column 12. Column 2 was used for the blank. To column PBS
was added to diminish interfering evaporation. On day 7, the incubation was terminated by washing the
plate twice with PBS. Subsequently the cells were fixed with 10% trichloroacetic acid in PBS and placed at
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4 C for one hour. After five washings with tap water, the cells were stained for at least 15 minutes with
0.4% SRB dissolved in 1% acetic acid. Atter staining the cells were washed with 1% acetic acid to remove
the unbound stain. The plates were air-dried and the bound stain was dissolved in 150 [al 10 mM Tris-base.
The absorbance was read at 540 nm using an automated mieroplate reader (Labsystems Multiskan MS).
Data were used for construction of concentration-response curves and determination of the IDs0 value by
use ofDeltasott 3 sottware.
Crystallography
A colourless crystal with dimensions 0.16 x 0.16 x 0.38 mm was used in the X-ray diffraction study. An
empirical absorption correction was applied [15]. The maximum residual electron density peak was located
in the vicinity ofthe gold atom.
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